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Introduction
The main findings of the study published by Hojo et al.1 in this edi-
tion of the journal are (i) valvular heart disease (VHD), and particu-
larly, aortic regurgitation (AR) and mitral regurgitation (MR) are
highly prevalent in patients with peripheral vascular disease
(PAD), and (ii) higher circulating levels of lipoprotein a (Lp(a))
are associated with increased risk of aortic (AS) and mitral (MS)
valve stenosis. In this large series of 861 patients with PAD re-
ferred to Kitakanto Hospital in Japan, 43.6% had VHD at echocar-
diographic examination: 26.8% AR, 19.7% MR, 5.9% AS, 1.3% MS,
and 9.4% tricuspid regurgitation (TR). Not surprisingly, older age
was associated with increased prevalence of all types of VHD, ex-
cept MS. Reduced glomerular filtration was associated with AR,
MR, and AS. However, the most striking observation of this study1
was that high levels of Lp(a) were independently associated with
increased prevalence of stenotic valvular lesions but not of regur-
gitant lesions.
Fibrocalcific degeneration of the aortic valve cusps is, by far, the
most frequent cause of AS.2 Although rheumatic disease remains
the most frequent aetiology of MS, degenerative disease may also
occur in elderly people. All cases of MS documented in the series
of Hojo et al.1 were of non-rheumatic aetiology. Degenerative MS
is characterized by calcification of the mitral annulus and of the leaf-
lets (predominantly at their base). With ageing of the population,
the prevalence of degenerative valvular stenosis (AS and/or MS)
has increased exponentially.2
No pharmacological treatment is currently available to prevent
the development or reduce the progression of AS or MS. Further-
more, in contrast to patients with rheumatic MS, those with
degenerative MS have no commissural fusion and are thus not
good candidates for percutaneous mitral commissurotomy.
Hence, valve replacement is generally the sole option currently
available for the treatment of severe symptomatic severe AS
or MS.
The role of Lp(a) in the
development of VHD
Previous studies suggest that AS is an actively regulated process that
involves several pathways including lipid infiltration, retention and
oxidation, inflammation, and fibrocalcific remodelling of the aortic
valve.3 Although data from animal models, Mendelian randomiza-
tion, and retrospective studies3,4 suggest that LDL-cholesterol could
be an important initiator of AS, three randomized clinical trials
(SALTIRE, SEAS, ASTRONOMER)5– 7 failed to demonstrate any sig-
nificant benefit of aggressive LDL-cholesterol-lowering therapy with
statins and/or fibrates in patients with mild to moderate AS. On the
other hand, recent studies reported that genetic variation in the LPA
locus, mediated by Lp(a) levels, is associated with higher incidence
of aortic sclerosis and AS in the general population.4,8,9 In a substudy
of ASTRONOMER, Capoulade et al.10 also reported that elevated
plasma level of Lp(a) is a powerful independent predictor of faster
AS progression, particularly in the younger patients. In contrast to
AS, there is relatively few published data on the pathophysiology
of degenerative MS. In the present study, Hojo et al.1 found that
Lp(a) is associated not only with AS but also with MS. These findings
would suggest that degenerative MS shares with AS some common
causative factors, including Lp(a). However, the study of Hojo et al.1
has some significant limitations including (i) the cross-sectional and
retrospective nature of the study, which precludes the demonstra-
tion of a cause–effect relationship between Lp(a) and stenotic
valvular lesions; and (ii) the very small number (n ¼ 11) of patients
with MS, which considerably limits the statistical power and thus the
robustness of the multivariable analysis for MS. In the large study by
Thanassoulis et al.,4 genetic variations in the LPA locus was not as-
sociated with mitral annulus calcification. However, this previous
study did not examine the association with MS. Despite its inherent
limitations, the study of Hojo et al.1 provides further support to the
concept that Lp(a) is a factor associated with the development of AS
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and, in addition, it raises the hypothesis that Lp(a) may also be in-
volved in the pathogenesis of degenerative MS.
About 20% of the general population have elevated Lp(a), and
there is now a large body of evidence in experimental and clinical
studies supporting the role of Lp(a) in the development of
coronary artery disease, PAD, and VHD.11 Among lipoproteins,
Lp(a) is the main carrier of oxidized phospholipids (OxPL) in
the bloodstream. When OxPL accumulate in the vascular or
valvular tissues, they are recognized by the immune system as
danger-associated molecular patterns (DAMPs). The response
of the immune system in trying to clear DAMPs is to generate
inflammation, which then mediates atherogenicity. Furthermore,
OxPL are transformed into lysophosphatidylcholine (LPC) by the
lipoprotein-associated phospholipase A2 (Lp-PLA2) enzyme. In
turn, LPC provides a substrate for the autotaxin enzyme, which
produces lysophosphatidic acid (LPA).12 Both LPC and LPA
have been shown to promote the osteogenic differentiation
and calcification of vascular and valvular cells. Hence, Lp(a)
and associated OxPL could, through their pro-inflammatory,
pro-atherogenic, and pro-calcifying properties, contribute to
the development of both PAD and degenerative stenotic valvular
lesions. On the other hand, these factors likely have little role in
the pathogenesis of regurgitant valvular lesions, which involve
more myxomatous degeneration rather than calcific degener-
ation. These findings may explain, at least in part, why in the study
of Hojo et al.1 Lp(a) was associated with AS and MS but not with
AR, MR, or TR.
Lp(a)-lowering therapy in VHD
When analysed collectively, the findings reported in the litera-
ture, including the present study,1,4,8 – 10,13 support a role for
Lp(a)/OxPL/LPC/LPA pathway in the development and progres-
sion of AS and thus provide an impetus for the realization of a
randomized clinical trial of Lp(a)-lowering therapy in this popula-
tion. However, the Lp(a) circulating levels are, in large part, de-
termined genetically, and currently available drugs such as niacin
only achieve minimal reduction in Lp(a) and have several import-
ant side effects. Recently, antisense oligonucleotide directed to
Apolipoprotein A has been developed and has been shown to
reduce Lp(a) levels by .80% with minimal side effects.14
PCSK9 inhibitors may also reduce Lp(a) by 20–30%. The next
step is to test the efficacy of these new drugs to slow the pro-
gression of AS.
Conclusion
The study of Hojo et al.1 provides further arguments to implement
systematic screening of Lp(a) in patients with PAD and/or VHD and
to undertake randomized trials to assess the effect of Lp(a)-lowering
therapy in patients with AS. This study also suggests that Lp(a) may
also be involved in the development of degenerative MS, but further
studies in larger series of patients are necessary to confirm this hy-
pothesis and eventually consider a Lp(a)-lowering trial targeting this
population.
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